Drug Overview
Alecensa (alectinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Roche and Chugai. In some non-small cell lung cancer (NSCLC) patients, abnormal ALK configuration leads to the production of proteins that promote and maintain the malignant behavior of cancer cells. In vitro studies have shown that Alecensa may be a stronger inhibitor of ALK than Xalkori (crizotinib; Pfizer/Merck KGaA), the current standard-of-care in ALK-positive NSCLC. Alecensa has also demonstrated efficacy against secondary mutations, such as L1196M, C1156Y, and F1174L, which typically confer resistance to Xalkori. Furthermore, second-generation ALK inhibitors have shown the ability to cross the blood-brain barrier and act on tumors in the central nervous system, a common site for distant metastases in ALK-positive NSCLC.
Alecensa (alectinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Roche and Chugai. In some non-small cell lung cancer (NSCLC) patients, abnormal ALK configuration leads to the production of proteins that promote and maintain the malignant behavior of cancer cells. In vitro studies have shown that Alecensa may be a stronger inhibitor of ALK than Xalkori (crizotinib; Pfizer/Merck KGaA), the current standard-of-care in ALK-positive NSCLC. Alecensa has also demonstrated efficacy against secondary mutations, such as L1196M, C1156Y, and F1174L, which typically confer resistance to Xalkori. Furthermore, second-generation ALK inhibitors have shown the ability to cross the blood-brain barrier and act on tumors in the central nervous system, a common site for distant metastases in ALK-positive NSCLC.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
